MX371329B - Factor de creciemiento similar a la insulina (igf) activo y su uso en infecciones por el virus del síndrome reproductivo y respiratorio porcino (prrsv). - Google Patents

Factor de creciemiento similar a la insulina (igf) activo y su uso en infecciones por el virus del síndrome reproductivo y respiratorio porcino (prrsv).

Info

Publication number
MX371329B
MX371329B MX2016007915A MX2016007915A MX371329B MX 371329 B MX371329 B MX 371329B MX 2016007915 A MX2016007915 A MX 2016007915A MX 2016007915 A MX2016007915 A MX 2016007915A MX 371329 B MX371329 B MX 371329B
Authority
MX
Mexico
Prior art keywords
animal
treating
methods
infection
infectious agent
Prior art date
Application number
MX2016007915A
Other languages
English (en)
Other versions
MX2016007915A (es
Inventor
D Hagen Chad
CASEBOLT Brett
Eldon Musser Robert
Original Assignee
Puretein Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puretein Bioscience Llc filed Critical Puretein Bioscience Llc
Publication of MX2016007915A publication Critical patent/MX2016007915A/es
Publication of MX371329B publication Critical patent/MX371329B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos para tratar a un animal utilizando una composición que incluye IGF activo. Los métodos incluyen tratar a un animal en riesgo de tener una infección causada por un agente infeccioso, tratar a un animal que tiene una infección y tratar un síntoma asociado con una infección. En una modalidad, el agente infeccioso es un virus. En una modalidad el protocolo de administración incluye administración diaria de por lo menos 0.05 nanogramos de IGF-1 activa por kilogramo de peso corporal del animal diariamente (en ng/kg), por lo menos 0.1 ng/kg, por lo menos 2 ng/kg, por lo menos 5 ng/kg o por lo menos 10 ng/kg.
MX2016007915A 2013-12-19 2014-12-19 Factor de creciemiento similar a la insulina (igf) activo y su uso en infecciones por el virus del síndrome reproductivo y respiratorio porcino (prrsv). MX371329B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361918405P 2013-12-19 2013-12-19
PCT/US2014/071387 WO2015095650A1 (en) 2013-12-19 2014-12-19 Methods for treating an animal

Publications (2)

Publication Number Publication Date
MX2016007915A MX2016007915A (es) 2016-10-07
MX371329B true MX371329B (es) 2020-01-27

Family

ID=53403728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007915A MX371329B (es) 2013-12-19 2014-12-19 Factor de creciemiento similar a la insulina (igf) activo y su uso en infecciones por el virus del síndrome reproductivo y respiratorio porcino (prrsv).

Country Status (8)

Country Link
US (2) US10279013B2 (es)
EP (1) EP3082841B1 (es)
KR (1) KR102313381B1 (es)
CN (1) CN106163538B (es)
CA (1) CA2933610C (es)
ES (1) ES2872998T3 (es)
MX (1) MX371329B (es)
WO (1) WO2015095650A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017012792A2 (pt) * 2014-12-16 2018-01-02 Puretein Bioscience Llc métodos para aumentar a concentração de igf, para tratar uma condição, para melhorar ou manter a saúde e para melhorar uma característica
BR112021012742A2 (pt) * 2018-12-31 2021-09-08 OmniGen Research, L.L.C. Suplementos alimentares
EP3976198A4 (en) 2019-05-31 2023-07-19 Viracta Subsidiary, Inc. METHODS OF TREATMENT OF VIRAL ASSOCIATED CANCER WITH HISTONE DEACETYLASE INHIBITORS
WO2022163852A1 (ja) * 2021-01-29 2022-08-04 株式会社 バイオミメティクスシンパシーズ アンジオテンシン転換酵素２（ａｃｅ２）及び／又はｔｍｐｒｓｓ２発現を阻害するための組成物
JP6953047B1 (ja) * 2021-03-08 2021-10-27 株式会社 バイオミメティクスシンパシーズ アンジオテンシン転換酵素２（ａｃｅ２）及び／又はｔｍｐｒｓｓ２発現を阻害するための組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025226A1 (en) * 1992-06-08 1993-12-23 Kabi Pharmacia Ab Use of growth factor igf-i and/or igf-ii
NZ243071A (en) * 1992-06-08 1994-09-27 Kabi Pharmacia Ab Igf-2 (or analogue) compositions for pharmaceutical uses
US5444045A (en) * 1992-09-17 1995-08-22 Gropep, Pty. Ltd. Method of administering IGF-1, IGF-2, and analogs thereof to birds
AUPP327198A0 (en) * 1998-04-30 1998-05-21 Northfield Laboratories Pty Ltd A food composition and method of using same
AUPQ585500A0 (en) * 2000-02-25 2000-03-16 Gropep Pty Ltd Treatment for peripheral sensory neuropathy
WO2002014473A2 (en) * 2000-08-15 2002-02-21 Board Of Trustees Of The University Of Illinois Animals expressing exogenous igf-i in their milk
EP1772464B1 (en) * 2001-02-09 2009-08-12 Genentech, Inc. Methods of identifying indirect agonists of IGF-1
NL1019143C2 (nl) 2001-10-08 2003-04-09 Nutricia Nv Farmaceutisch product of voedingssupplement en daarbij te gebruiken tussenproduct.
PT1670444E (pt) * 2003-10-03 2011-07-29 Veijlen N V Utilização de derivados do ácido indoleacético que aumentam o nível de igf-1 no soro para a preparação de uma composição terapêutica para o tratamento de várias doenças
ES1056525Y (es) * 2004-01-13 2004-07-16 Perez Alfredo Pineiro Halador de tres rodillos para redes y aparejos de pesca.
ITMI20052204A1 (it) 2005-11-18 2007-05-19 Umberto Cornelli Uso di colostro per la profilassi delle sindroni influenzali
CN101466398A (zh) * 2006-06-09 2009-06-24 诺瓦提斯公司 稳定的胰岛素样生长因子多肽
US8343918B2 (en) * 2006-06-09 2013-01-01 Novartis Ag Stabilized insulin-like growth factor polypeptides
WO2008016958A2 (en) * 2006-08-01 2008-02-07 Minitube Of America, Inc. Reproductive cell media compositions and methods for improving fertility
US8475789B2 (en) * 2008-01-22 2013-07-02 Multimerics Aps Products and methods to prevent infections
US20110152188A1 (en) 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
ES2674439T3 (es) * 2011-06-01 2018-06-29 Merial, Inc. Administración sin aguja de vacunas contra el VSRRP
US20130345113A1 (en) 2011-07-13 2013-12-26 Ronald E. Strohbehn Method of Use of Activated Functional Proteins to Improve Animal Health
EP2763692A2 (en) * 2011-10-06 2014-08-13 European Molecular Biology Laboratory Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases

Also Published As

Publication number Publication date
US20160317624A1 (en) 2016-11-03
EP3082841A1 (en) 2016-10-26
CN106163538B (zh) 2020-03-17
EP3082841A4 (en) 2017-07-26
CA2933610C (en) 2023-01-24
MX2016007915A (es) 2016-10-07
ES2872998T3 (es) 2021-11-03
US10279013B2 (en) 2019-05-07
KR102313381B1 (ko) 2021-10-14
CN106163538A (zh) 2016-11-23
US20190209658A1 (en) 2019-07-11
CA2933610A1 (en) 2015-06-25
KR20160098492A (ko) 2016-08-18
EP3082841B1 (en) 2021-03-17
WO2015095650A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
CL2019001433A1 (es) Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684)
MX371329B (es) Factor de creciemiento similar a la insulina (igf) activo y su uso en infecciones por el virus del síndrome reproductivo y respiratorio porcino (prrsv).
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
PH12019500513A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
PH12015502230B1 (en) Novel viral replication inhibitors
MX2016004492A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
MX2015012536A (es) Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc.
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
TW201613592A (en) Glucose metabolism ameliorating agent
WO2016044839A3 (en) Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
MX2018000240A (es) Metodos para tratar el vhc.
MX2015007065A (es) Metodo y composiciones para tratar diarrea asociada con vih.
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
BR112017023425A2 (pt) combinações terapêuticas de terapias antivirais e anti-inflamatórias
PH12015502128A1 (en) Novel dosing regimens of celgosivir for the treatment of dengue
MX369039B (es) Vacuna contra el circovirus porcino tipo 2.
EP4282485A3 (en) Dosage regimen for pegylated interferon
WO2015120127A3 (en) Treating flavivirus infections with amodiaquine and derivatives thereof
WO2014140680A8 (en) Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection
BR112017019758A2 (pt) tratamento combinado com um agonista tlr7 e um inibidor de conjunto de capsídeo de hbv
BR112017018977A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de uma infecção por hepatite c ou uma condição resultante de uma infecção por hepatite c, em um hospedeiro em necessidade do mesmo e para fabricação de um medicamento direcionado para uso terapêutico para tratamento de uma infecção pelo vírus da hepatite c, uso de um composto, e, formulação farmacêutica?.
BR112016020895A2 (pt) moduladores alostéricos da proteína do núcleo da hepatite b

Legal Events

Date Code Title Description
FG Grant or registration